PMID- 32611246
OWN - NLM
STAT- MEDLINE
DCOM- 20211214
LR  - 20211214
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 50
IP  - 5
DP  - 2021 Jul
TI  - Effects of Complement Regulators and Chemokine Receptors in Type 2 Diabetes.
PG  - 478-491
LID - 10.1080/08820139.2020.1778022 [doi]
AB  - CD55 and CD59 are complement regulatory proteins suggested to be related with 
      progression of diabetes and its complications. The stromal cell-derived factor 1 
      (SDF-1) and C-X-C chemokine receptor type 4 (CXCR-4) are chemokine proteins. We 
      aimed to investigate the relation of CD55 and CD59 expression levels and 
      polymorphisms of SDF-1 and CXCR-4 with type 2 diabetes mellitus (T2DM) and its 
      complications. Seventy-five T2DM patients and 73 controls were enrolled. 
      Expression levels of CD55 and CD59 were measured by FACS Calibur; qRT-PCR was 
      used to determine SDF-1 and CXCR-4 gene polymorphisms. CD55 and CD59 expressions 
      in patients with nephropathy, retinopathy and cardiovascular disease were 
      significantly lower than controls. Frequency of CXCR-4 T allele carrying was high 
      in patients and created 1.6 fold risk for the disease (p = .07). CXCR-4 a allele 
      carriers had decreased nephropathy; although there was no statistical 
      significance in carrying CXCR-4 T allele, presence of nephropathy was 
      approximately 2 times higher (p = .254). The nephropathy risk increased 10-fold 
      in CXCR-4 TT genotype carriers (p = .02). All SDF-1 CC genotype carriers had 
      retinopathy, so, it was considered that the CC genotype was effective in 
      retinopathy development (p = .031). For the presence of cardiovascular disease, 
      significant difference was observed for SDF-1 genotypes. Increased cardiovascular 
      risk of 5- and 1.9-fold in SDF-1 T (p = .007) and CXCR-4 T (p = .216) allele 
      carriers, respectively, was observed. We suggest that CD55 and CD59 protein 
      levels and SDF-1 and CXCR-4 have predictive importance in process, complications 
      and tendency of T2DM.
FAU - Aydin Ozgur, B
AU  - Aydin Ozgur B
AUID- ORCID: 0000-0003-0513-0384
AD  - Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 
      Istanbul University, Istanbul, Turkey.
AD  - Department of Medical Biology and Genetics, Faculty of Medicine, Demiroglu Bilim 
      University, Istanbul, Turkey.
FAU - Coskunpinar, E
AU  - Coskunpinar E
AUID- ORCID: 0000-0002-1003-5544
AD  - Department of Medical Biology, Faculty of Medicine, Health Science University, 
      Istanbul, Turkey.
FAU - Bilgic Gazioglu, S
AU  - Bilgic Gazioglu S
AUID- ORCID: 0000-0003-1950-0948
AD  - Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 
      Istanbul University, Istanbul, Turkey.
FAU - Yilmaz, A
AU  - Yilmaz A
AUID- ORCID: 0000-0002-3003-9956
AD  - Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 
      Istanbul University, Istanbul, Turkey.
FAU - Musteri Oltulu, Y
AU  - Musteri Oltulu Y
AUID- ORCID: 0000-0001-8248-2100
AD  - Department of Medical Biology, Faculty of Medicine, Biruni University, Istanbul, 
      Turkey.
FAU - Cakmakoglu, B
AU  - Cakmakoglu B
AUID- ORCID: 0000-0001-7960-9131
AD  - Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, 
      Istanbul University, Istanbul, Turkey.
FAU - Deniz, G
AU  - Deniz G
AUID- ORCID: 0000-0002-0721-6213
AD  - Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 
      Istanbul University, Istanbul, Turkey.
FAU - Gurol, A O
AU  - Gurol AO
AUID- ORCID: 0000-0001-6682-4289
AD  - Department of Immunology, Aziz Sancar Institute of Experimental Medicine, 
      Istanbul University, Istanbul, Turkey.
FAU - Yilmaz, M T
AU  - Yilmaz MT
AUID- ORCID: 0000-0002-6130-947X
AD  - Department of Endocrinology and Metabolism, Faculty of Istanbul Medicine, 
      Internal Medicine, Istanbul University, Istanbul, Turkey.
AD  - Department of Endocrinology and Metabolism, Faculty of Medicine, Internal 
      Medicine, Demiroglu Bilim University, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200702
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (CD55 Antigens)
RN  - 0 (CD59 Antigens)
RN  - 0 (CXCL12 protein, human)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Receptors, CXCR4)
SB  - IM
MH  - Aged
MH  - CD55 Antigens/genetics/*metabolism
MH  - CD59 Antigens/genetics/*metabolism
MH  - Cardiovascular Diseases/*genetics
MH  - Chemokine CXCL12/*genetics
MH  - Diabetes Mellitus, Type 2/*immunology
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - *Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Receptors, CXCR4/*genetics
OTO - NOTNLM
OT  - CD55
OT  - CD59
OT  - CXCR-4
OT  - SDF-1
OT  - Type 2 diabetes
EDAT- 2020/07/03 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.1080/08820139.2020.1778022 [doi]
PST - ppublish
SO  - Immunol Invest. 2021 Jul;50(5):478-491. doi: 10.1080/08820139.2020.1778022. Epub 
      2020 Jul 2.